FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313649095> ?p ?o ?g. }

• W4313649095 endingPage "425" @default.
• W4313649095 startingPage "415" @default.
• W4313649095 abstract "Direct oral anticoagulants (DOACs) used in nonvalvular atrial fibrillation (NVAF) are dose-reduced in elderly and patients with impaired renal function. Only reduced dose dabigatran is concluded as having similar stroke risk reduction and lower risk of major bleeding than warfarin in the pivotal studies. In clinical practice, reduced dose is prescribed more often than expected making this an important issue. The objective of this study was to compare effectiveness and safety between reduced dose DOACs and high TTR warfarin treatment (TTR ≥ 70%) in NVAF. A Swedish anticoagulation registry was used in identifying eligible patients from July 2011 to December 2017. The study cohort consisted of 40,564 patients with newly initiated DOAC (apixaban, dabigatran, or rivaroxaban) (11,083 patients) or warfarin treatment (29,481 patients) after exclusion of 374,135 patients due to not being warfarin or DOAC naïve, not being prescribed reduced dose, having previous mechanical heart valve (MHV), or being under 18 years old. The median durations of follow up were 365, 419, 432 and 473 days for apixaban, dabigatran, rivaroxaban and warfarin, respectively. Warfarin TTR identified from Auricula was 70.0%. Endpoints (stroke and major bleeding) and baseline characteristics were collected from hospital administrative registers using ICD-10 codes. Cohorts were compared using weighted adjusted Cox regression after full optimal matching based on propensity scores. DOACs are associated with lower risk of major bleeding (HR with 95% CI) 0.85 (0.78-0.93), intracranial bleeding HR 0.64 (0.51-0.80), hemorrhagic stroke HR 0.68 (0.50-0.92), gastrointestinal bleeding HR 0.81 (0.69-0.96) and all-cause stroke HR 0.87 (0.76-0.99), than warfarin. Apixaban and dabigatran are associated with lower risk of major bleeding, HR 0.70 (0.63-0.78) and HR 0.80 (0.69-0.94), and rivaroxaban is associated with lower risk of ischemic stroke, HR 0.73 (0.59-0.96), with higher major bleeding risk, HR 1.31 (1.15-1.48), compared to warfarin. Apixaban is associated with higher all-cause mortality compared to warfarin, HR 1.12 (1.03-1.21). DOACs are associated with lower risk of major bleeding and all-cause stroke, than high quality warfarin treatment, with exception of rivaroxaban that carried higher risk of major bleeding and lower risk of stroke or systemic embolism. In this large observational registry-based NVAF cohort, DOACs are preferred treatment in patients with indication for DOAC dose reduction, even in a high TTR setting." @default.
• W4313649095 created "2023-01-07" @default.
• W4313649095 creator A5005967309 @default.
• W4313649095 creator A5009999314 @default.
• W4313649095 creator A5019914133 @default.
• W4313649095 creator A5038271770 @default.
• W4313649095 creator A5067654386 @default.
• W4313649095 creator A5076436604 @default.
• W4313649095 creator A5088605272 @default.
• W4313649095 date "2023-01-06" @default.
• W4313649095 modified "2023-10-01" @default.
• W4313649095 title "Reduced dose direct oral anticoagulants compared with warfarin with high time in therapeutic range in nonvalvular atrial fibrillation" @default.
• W4313649095 cites W1605933709 @default.
• W4313649095 cites W1924098982 @default.
• W4313649095 cites W1999468381 @default.
• W4313649095 cites W2006640042 @default.
• W4313649095 cites W2014924181 @default.
• W4313649095 cites W2020148377 @default.
• W4313649095 cites W2030466875 @default.
• W4313649095 cites W2031717872 @default.
• W4313649095 cites W2050405051 @default.
• W4313649095 cites W2055586130 @default.
• W4313649095 cites W2067408747 @default.
• W4313649095 cites W2068323363 @default.
• W4313649095 cites W2080111455 @default.
• W4313649095 cites W2081134280 @default.
• W4313649095 cites W2085706006 @default.
• W4313649095 cites W2096246254 @default.
• W4313649095 cites W2097854437 @default.
• W4313649095 cites W2110842207 @default.
• W4313649095 cites W2114775432 @default.
• W4313649095 cites W2118243040 @default.
• W4313649095 cites W2122771444 @default.
• W4313649095 cites W2123257771 @default.
• W4313649095 cites W2129962350 @default.
• W4313649095 cites W2132505348 @default.
• W4313649095 cites W2136489990 @default.
• W4313649095 cites W2137878797 @default.
• W4313649095 cites W2139577967 @default.
• W4313649095 cites W2143034000 @default.
• W4313649095 cites W2149388786 @default.
• W4313649095 cites W2152623033 @default.
• W4313649095 cites W2162269364 @default.
• W4313649095 cites W2162508946 @default.
• W4313649095 cites W2165762371 @default.
• W4313649095 cites W2166018731 @default.
• W4313649095 cites W2171626452 @default.
• W4313649095 cites W2221119008 @default.
• W4313649095 cites W2340635798 @default.
• W4313649095 cites W2433454023 @default.
• W4313649095 cites W2442037294 @default.
• W4313649095 cites W2471768068 @default.
• W4313649095 cites W2526462686 @default.
• W4313649095 cites W2529460814 @default.
• W4313649095 cites W2566947560 @default.
• W4313649095 cites W2588211211 @default.
• W4313649095 cites W2588984358 @default.
• W4313649095 cites W2595447138 @default.
• W4313649095 cites W2622276831 @default.
• W4313649095 cites W2735328384 @default.
• W4313649095 cites W2750856436 @default.
• W4313649095 cites W2769275060 @default.
• W4313649095 cites W2790375504 @default.
• W4313649095 cites W2805259111 @default.
• W4313649095 cites W2898680801 @default.
• W4313649095 cites W2906193835 @default.
• W4313649095 cites W2959714206 @default.
• W4313649095 cites W2983944525 @default.
• W4313649095 cites W2995590065 @default.
• W4313649095 cites W3014410091 @default.
• W4313649095 cites W3016946377 @default.
• W4313649095 cites W3034320327 @default.
• W4313649095 cites W3036771219 @default.
• W4313649095 cites W3119149480 @default.
• W4313649095 doi "https://doi.org/10.1007/s11239-022-02763-w" @default.
• W4313649095 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36607464" @default.
• W4313649095 hasPublicationYear "2023" @default.
• W4313649095 type Work @default.
• W4313649095 citedByCount "3" @default.
• W4313649095 countsByYear W43136490952023 @default.
• W4313649095 crossrefType "journal-article" @default.
• W4313649095 hasAuthorship W4313649095A5005967309 @default.
• W4313649095 hasAuthorship W4313649095A5009999314 @default.
• W4313649095 hasAuthorship W4313649095A5019914133 @default.
• W4313649095 hasAuthorship W4313649095A5038271770 @default.
• W4313649095 hasAuthorship W4313649095A5067654386 @default.
• W4313649095 hasAuthorship W4313649095A5076436604 @default.
• W4313649095 hasAuthorship W4313649095A5088605272 @default.
• W4313649095 hasBestOaLocation W43136490951 @default.
• W4313649095 hasConcept C126322002 @default.
• W4313649095 hasConcept C127413603 @default.
• W4313649095 hasConcept C164705383 @default.
• W4313649095 hasConcept C17923572 @default.
• W4313649095 hasConcept C2776301958 @default.
• W4313649095 hasConcept C2778661090 @default.
• W4313649095 hasConcept C2778810321 @default.
• W4313649095 hasConcept C2779161974 @default.
• W4313649095 hasConcept C2780638905 @default.

• next